Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension

While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with pulm...

Descripción completa

Detalles Bibliográficos
Autores principales: Morland, Kellie, Raina, Amresh, Nails, Abigail, Classi, Peter, Etschmaier, Martine, Frantz, Robert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743947/
https://www.ncbi.nlm.nih.gov/pubmed/35024138
http://dx.doi.org/10.1177/20458940211046761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743947/
https://www.ncbi.nlm.nih.gov/pubmed/35024138
http://dx.doi.org/10.1177/20458940211046761

Ejemplares similares